Adjuvant Breast Cancer Therapy for Premenopausal Women
Name of the Trial
Why Is This Trial Important?
Recently, a new class of drugs called aromatase inhibitors was shown to improve disease-free survival in postmenopausal women with endocrine-responsive cancers. However, aromatase inhibitors are not effective in premenopausal women because their ovaries are still producing estrogen.
In this trial, researchers will study three groups of premenopausal women with endocrine-responsive breast cancer. Menopause will be induced in two of the groups; one group will be treated with tamoxifen, the other with the aromatase inhibitor exemestane. Menopause will not be induced in the third group, which will be treated with tamoxifen. The researchers hope to determine which treatment approach is most effective in preventing breast cancer recurrence in premenopausal women.
"Young women with endocrine-responsive breast cancer have a high risk for recurrence if not treated with antihormone therapy," said Dr. Fleming. "We are trying to explore ways to improve that therapy for these patients."
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.